MetaCap

Aura Biosciences (AURA) vs MeiraGTx (MGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aura Biosciences (AURA) has outperformed MeiraGTx (MGTX) over the past year, gaining 26.3% versus a gain of 7.0%. Over five years, MGTX leads with a -55.5% price change compared with -69.6% for AURA. MeiraGTx is the larger company by market cap ($779.9 million vs $715.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+26.29%MGTX+6.97%
+106%+46%-14%
Nov 21, 20251 yearNov 20, 2026
AURA-69.47%MGTX-57.21%
+33%-26%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus MGTX key metrics
MetricAURAMGTX
Share price$6.87$7.98
Market cap$714.99M$779.89M
1-day change-1.58%-1.97%
YTD return+26.06%+0.38%
1-year return+26.29%+6.97%
5-year return-69.63%-55.54%
P/E ratio (TTM)—9.17
EPS (TTM)$-1.59$0.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$81.39M
Revenue growth (YoY)—+144.57%
Net income (latest FY)$-106.19M$-114.20M
Operating margin—-130.20%
Net margin—-140.31%
52-week high$9.54$15.35
52-week low$4.73$6.62
Distance from 52-week high-27.95%-48.01%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+141.63%+247.74%
Average volume847.22K837.25K
Shares outstanding104.07M97.73M
Employees113386
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AURA has outperformed MGTX by 19.3 percentage points over the past year.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About MeiraGTx

MGTX stock →

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees

AURA vs MGTX FAQ

Which is bigger, Aura Biosciences or MeiraGTx?

MeiraGTx (MGTX) is larger, with a market capitalization of $779.89M compared with $714.99M for Aura Biosciences (AURA).

Which stock has performed better over the past year, AURA or MGTX?

AURA returned +26.29% over the past 12 months, compared with +6.97% for MGTX (price return, excluding dividends). Past performance does not predict future results.

Are Aura Biosciences and MeiraGTx in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons